Jun 8
NewLimit raises $435M Series C for epigenetic programming, liver cell-age reprogramming, and aging therapeutics targeting human clinical trials.
#Longevity #Biotech #EpigeneticProgramming #CellularReprogramming #AgingTherapeutics #NewLimit
18
The Famine Ended 70 Years Ago, but Dutch Genes Still Bear Scars nytimes.com/2018/01/31/scien… #DOHaD #epigeneticprogramming
3
4